SUPN compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name

SUPNSupernus Pharmaceuticals, Inc.

Mkt capRevenueRevenue

LLYELI Lilly & Co

Mkt capRevenueRevenue

Compare

SUPNSupernus Pharmaceuticals, Inc.

LLYELI Lilly & Co

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

SUPN

0 of 2at or beyond implied

Reportimpliedrealized× implied

Oct 30 '26—▲+0.19%—

Q3 FY26—▲+3.49%—

Aug 3 '26±11.3%▲+3.07%×0.27

Q2 FY26±11.3%▲+0.53%×0.04

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

= impliedSUPN realized, solidLLY realized, hatchedOne scale, both sides: full bar = 12%× = |realized| ÷ impliedspan: SUPN 99d · LLY 267dSource: market data

Q1 FY26

±5.3%

▲+9.80%

×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

SUPNSupernus Pharmaceuticals, Inc.

26.15· pre 26.15· delayed

Mkt cap$3.1BRevenue$356MQ3 FY26Revenue$719MFY25

LLYELI Lilly & Co

1,360.90· pre 1,391.54· delayed

Pre-marketNov 9 '26delayed

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

Compare

Pre-marketNov 9 '26delayed

SUPNSupernus Pharmaceuticals, Inc.

LLYELI Lilly & Co

26.15pre 26.15delayed

Price

1,360.90pre 1,391.54delayed

$3.1B

Mkt cap

$1.2T

Q3 FY26$356M

Revenue

$24.4BQ3 FY26

FY25$719M

Revenue

$65.2BFY25

SUPN26.15vsLLY1,360.90Pre-marketNov 9 '26delayed